Treatment of malaria both vivax and falciparum
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Searching PubMed
malaria treatment WHO guidelines 2023
Reading File
Reading File
Reading File
I now have comprehensive material to compose a thorough answer. Here is the complete guide to malaria treatment:
Treatment of Malaria: P. vivax and P. falciparum
Overview
Malaria treatment depends on the infecting species, disease severity, geographic resistance patterns, and the patient's profile (pregnancy, G6PD status, age). The key principle is that all fever cases confirmed by microscopy or RDT should receive prompt, effective treatment - presumptive treatment is no longer recommended.
1. P. VIVAX MALARIA (Uncomplicated)
First-Line Treatment
Chloroquine (CQ) + Primaquine (PQ)
Chloroquine remains the backbone of P. vivax treatment in most countries (resistance is rising in Papua New Guinea, Indonesia, and parts of South America but is still rare in India).
| Drug | Dose | Schedule |
|---|---|---|
| Chloroquine | 25 mg/kg total over 3 days | 10 mg/kg on Day 1, 10 mg/kg on Day 2, 5 mg/kg on Day 3 |
| Primaquine | 0.25 mg/kg/day | Days 1-14 (14-day course for radical cure) |
- Chloroquine clears the blood stage (asexual parasites), terminating fever within 24-48 hours and clearing parasitemia in 48-72 hours.
- Primaquine is essential to eliminate hypnozoites (dormant liver forms) which cause relapse. The relapse rate in India is approximately 30%.
Age-Based Dosing Chart (India - Park's)
| Age | CQ Day 1 (150 mg tabs) | CQ Day 2 | CQ Day 3 | PQ (2.5 mg tabs) Days 1-14 |
|---|---|---|---|---|
| <1 year | ½ tab | ½ tab | ¼ tab | None (contraindicated) |
| 1-4 years | 1 tab | 1 tab | ½ tab | 1 tab |
| 5-8 years | 2 tabs | 2 tabs | 1 tab | 2 tabs |
| 9-14 years | 3 tabs | 3 tabs | 1.5 tabs | 4 tabs |
| ≥15 years | 4 tabs | 4 tabs | 2 tabs | 6 tabs |
| Pregnancy | 4 tabs | 4 tabs | 2 tabs | 0 (PQ contraindicated) |
Chloroquine-Resistant Vivax
- Treat with the same ACTs used for falciparum malaria (artemether-lumefantrine, artesunate-mefloquine, dihydroartemisinin-piperaquine).
- Follow with primaquine for radical cure.
Alternative for Radical Cure: Tafenoquine
- Single-dose alternative to 14-day primaquine (300 mg single dose in adults). Must test G6PD status before use (same hemolysis risk as primaquine).
2. P. FALCIPARUM MALARIA (Uncomplicated)
Artemisinin-Based Combination Therapy (ACT) - The Global Standard
ACT is recommended in nearly all countries with endemic P. falciparum. Artemisinin monotherapy is strongly discouraged (banned in India) as it promotes resistance. The combination extends the partner drug's efficacy and reduces gametocyte carriage.
Regimens by Region
India (Non-North-Eastern States): ACT-SP
| Drug | Dose | Days |
|---|---|---|
| Artesunate (AS) | 4 mg/kg/day | Days 1, 2, 3 |
| Sulfadoxine-Pyrimethamine (SP) | 25 mg/kg sulfa / 1.25 mg/kg pyrimethamine | Day 1 only |
| Primaquine (PQ) | 0.75 mg/kg single dose | Day 2 (as gametocytocide) |
India (North-Eastern States): ACT-AL (due to SP resistance)
| Drug | Dose |
|---|---|
| Artemether (20 mg) + Lumefantrine (120 mg) | Age-specific dosing for 3 days |
| Primaquine | Single dose on Day 2 |
Note: ACT-AL is not recommended in the first trimester or in children weighing <5 kg.
Globally Available First-Line ACTs (WHO-recommended)
| Regimen | Notes |
|---|---|
| Artemether-lumefantrine (Coartem) | Only ACT approved in the US; take with fatty food |
| Artesunate-amodiaquine | Widely used in Africa |
| Artesunate-mefloquine | Used in Southeast Asia |
| Dihydroartemisinin-piperaquine (DHA-PPQ) | Efficacy declining in SE Asia due to resistance |
| Artesunate-pyronaridine | No confirmed falciparum resistance to pyronaridine yet |
ACT Dosage Chart for Falciparum (India - ACT-SP)
| Age | Day 1: AS | Day 1: SP | Day 2: AS | Day 2: PQ | Day 3: AS |
|---|---|---|---|---|---|
| 0-1 yr (Pink) | 25 mg | 250+12.5 mg | 25 mg | Nil | 25 mg |
| 1-4 yr (Yellow) | 50 mg | 500+25 mg | 50 mg | 7.5 mg base | 50 mg |
| 5-8 yr (Green) | 100 mg | 750+37.5 mg | 100 mg | 15 mg base | 100 mg |
| 9-14 yr (Red) | 150 mg | 500+25 mg x2 | 150 mg | 30 mg base | 150 mg |
| ≥15 yr (White) | 200 mg | 750+37.5 mg x2 | 200 mg | 45 mg base | 200 mg |
Alternative: Quinine + Doxycycline (or Clindamycin)
Used when ACT is unavailable or in specific populations:
- Quinine 10 mg/kg TID for 7 days + Doxycycline 100 mg OD for 7 days
- Replace doxycycline with clindamycin in pregnant women and children <8 years
- Clindamycin 10 mg/kg 12-hourly for 7 days
Note on Artemisinin Resistance
- Kelch13 (K13) gene mutations causing delayed parasite clearance have emerged in Southeast Asia (Cambodia, Thailand, Myanmar, Vietnam).
- High clinical failure rates with DHA-piperaquine documented in parts of SE Asia.
- Emerging K13-mutant parasites now detected in Rwanda and Uganda (Africa) - closely monitored but ACT efficacy not yet significantly affected there.
3. SEVERE MALARIA (Medical Emergency - Primarily P. falciparum)
Clinical Features of Severe Malaria
Suspect severe malaria in P. falciparum infection if any of the following are present:
- Impaired consciousness / coma (cerebral malaria)
- Repeated generalized convulsions
- Renal failure (creatinine >3 mg/dL)
- Jaundice (bilirubin >3 mg/dL)
- Severe anemia (Hb <5 g/dL)
- Pulmonary edema / ARDS
- Hypoglycemia (glucose <40 mg/dL)
- Circulatory collapse (SBP <80 mmHg; <50 mmHg in children)
- Hyperparasitemia (>5% parasitized RBCs in low-endemic, >10% in high-endemic areas)
- Hemoglobinuria, abnormal bleeding, DIC, hyperthermia (>42°C)
Parenteral Treatment (Initial - at least 48 hours)
First choice: IV Artesunate
- 2.4 mg/kg IV or IM at 0, 12, and 24 hours, then once daily
- Superior to quinine in all clinical trials for severe malaria (reduces mortality by ~25%)
- First-line in the US and globally per WHO
Alternatives if artesunate unavailable:
- Artemether: 3.2 mg/kg IM on Day 1, then 1.6 mg/kg/day IM
- Arteether: 150 mg IM daily for 3 days (adults only, not children)
- Quinine: 20 mg/kg loading dose (IV infusion or divided IM) on admission, then 10 mg/kg every 8 hours (infusion rate must not exceed 5 mg/kg/hour)
Important: Minimum 24 hours of parenteral therapy regardless of clinical improvement.
Step-Down Oral Treatment (after parenteral phase)
- After IV artesunate: complete full course of area-specific ACT (3 days)
- After quinine: continue oral quinine 10 mg/kg TID + doxycycline/clindamycin to complete 7 total days
Supportive Care in Severe Malaria
- Fluid and electrolyte management (avoid aggressive fluid overload)
- Glucose monitoring and replacement (hypoglycemia is common, especially with quinine)
- Anticonvulsants for seizures
- Respiratory support / mechanical ventilation if needed
- Hemodialysis / hemofiltration for acute kidney injury
- Antibiotics if sepsis is suspected (coinfection is common)
- Avoid blood transfusion unless severe anemia (Hb <5 g/dL)
4. SPECIAL SITUATIONS
Malaria in Pregnancy
| Trimester | P. falciparum | P. vivax |
|---|---|---|
| 1st Trimester | Quinine + Clindamycin (7 days); ACT avoided | Chloroquine (safe) |
| 2nd & 3rd Trimester | ACT (preferred) | Chloroquine |
- Primaquine is contraindicated in all trimesters
- Severe malaria in any trimester: artemisinin derivatives are preferred over quinine (quinine worsens hypoglycemia in pregnancy)
Mixed Infections (P. falciparum + P. vivax)
Treat as P. falciparum malaria using ACT.
G6PD Deficiency
- Primaquine is contraindicated - causes severe hemolysis
- Screen for G6PD deficiency before giving primaquine (especially important in high-prevalence areas)
- Warning signs of hemolysis: dark urine, jaundice, abdominal pain, cyanosis of lips
Infants (<1 year)
- Primaquine is contraindicated
5. DRUG MECHANISMS SUMMARY
| Drug | Target / Mechanism |
|---|---|
| Chloroquine | Concentrates in parasite food vacuole; inhibits heme biocrystallization (hemozoin formation) → free heme accumulation is toxic to parasite |
| Artemisinins | Free radical generation activated by heme iron; kills blood stages rapidly including ring forms |
| Primaquine | Tissue schizonticide and hypnozoiticide; eliminates liver stages; also gametocytocidal |
| Sulfadoxine-Pyrimethamine | Folate synthesis inhibition (dihydropteroate synthase + DHFR) |
| Lumefantrine, Mefloquine, Piperaquine | Aminoalcohol / aminoquinoline blood schizonticides; act on heme detoxification |
| Quinine | Blood schizonticide; inhibits hemozoin formation; negative chronotrope / inotrope (cardiac risk) |
| Doxycycline | Protein synthesis inhibitor (30S ribosome); slow-acting, used as combination partner only |
6. RESISTANCE MONITORING AND KEY ALERTS
- Chloroquine resistance in P. falciparum: mediated by PfCRT mutations; now nearly universal except Central America and the Caribbean.
- SP resistance: common in Northeast India and Southeast Asia. Use ACT-AL in those regions.
- Artemisinin partial resistance: kelch13 mutations, first in Cambodia/Thailand, now detected in parts of Africa (Rwanda, Uganda). ACT still largely effective but monitor closely.
- Tafenoquine (2018 approval): single-dose alternative to 14-day primaquine for P. vivax radical cure; requires same G6PD precautions.
Sources: Park's Textbook of Preventive and Social Medicine (India Drug Policy 2013, revised guidelines); Goldman-Cecil Medicine International Edition; Katzung's Basic and Clinical Pharmacology, 16th ed.
Recent evidence note: A 2024 Lancet Infectious Diseases systematic review (PMID 37748497) confirms that standard-dose primaquine (0.25 mg/kg/day x 14 days) is safer than high-dose regimens in G6PD-heterozygous women, supporting continued use of the weight-based schedule above.
This is a shared conversation. Sign in to Orris to start your own chat.